India Post, Apollo Cancer Centres Chennai to launch 'Stamp Out Childhood Cancer' campaign

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Truqap plus Faslodex approved in the US for patients with advanced HR-positive breast cancer

First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients

Health Minister Mandaviya delivers keynote address 2nd Voice of Global South Summit 2023

Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure

Teva announces approval of a generic version of Forteo in US

This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24

Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024